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Abstract:	Recent	evidence	suggests	that	neuroinflammation	and	immunity	play	a	significant	role	in	Alzheimer’s	disease	(AD)	and	other	neurodegenerative	diseases.		It	has	also	been	 observed	 that,	 independent	 of	 the	 presence	 of	 aggregated	 proteins,	neuroinflammation	could	be	present	 in	different	neurodegenerative	diseases.	 It	has	 also	 been	 suggested	 that	 neuroinflammation	 could	 occur	 well	 ahead	 of	amyloid	 deposition	 in	AD.	 Recent	 genetic	 studies	 and	 other	 preclinical	 studies	specifically	point	to	a	role	of	neuroinflammation	and,	in	this	review,	we	evaluate	the	evidence	of	neuroinflammation	in	the	Alzheimer’s	disease	trajectory	and	the	different	 imaging	modalities	by	which	we	could	monitor	neuroinflammation	 in	vivo	in	humans.			
Introduction	Neuroinflammation	is	an	innate	response	in	the	central	nervous	system	against	harmful	 changes	 in	 brain	 milieu	 such	 as	 formation	 of	 abnormal	 protein	aggregates,	 invasion	 of	 pathogens,	 traumatic	 and	 vascular	 lesions,	 and	autoimmune	responses	to	brain	material	such	as	myelin.	It	has	been	proposed	that	intrinsic	 neuroinflammation	 in	 the	 form	 of	 glial	 activation	 is	 a	 component	 of	neurodegenerative	 diseases	 such	 as	 Alzheimer's	 disease	 and	 other	 dementias,	Parkinsonian	 disorders,	 and	 Huntington's	 disease.	 While	 there	 are	 several	mediators	of	inflammation	which	lead	to	neuronal	damage,	the	pro-inflammatory	cytokines	and	interleukin-1	β,	IL-1,	IL-8,	and	IL-33	play	a	significant	role.		While	 neuroinflammation	 is	 a	 response	 that	 involves	 all	 cells	 present	 within	affected	region	of	 the	central	nervous	system,	including	neurons,	microglia	and	other	 inflammatory	 cells,	 there	 are	 several	 factors	 which	 influence	 how	neuroinflammation	 affects	 the	 neurodegenerative	 process.	 These	 include	environmental	factors,	previous	immune	sensitisation,	genetic	factors,	epigenetic	factors	and	several	intrinsic	and	extrinsic	factors.	Preclinical	models	have	shown	that	 lipopolysaccharide	 can	 induce	 toll-like	 receptor	 protein	 (TLR)	 signalling,	which	activates	several	signal	transduction	pathways	including	protein	kinase	B,	mitogen	protein	activated	kinase	and	mammalian	target	of	rapamycin	(mTOR)	in	turn	 activating	 NF-κb.	 NF-κb	 mediates	 production	 of	 cytokines,	 chemokines,	inducible	nitric	oxide	synthase	and	cox2	promoting	neurodegenerative	processes.		There	are	several	players	involved	in	intrinsic	neuroinflammatory	process:		these	include	microglia,	astrocytes,	oligodendrocytes	and	inflammatory	mediators	such	as	cytokines,	chemokines	and	lipopolysaccharides.	
	
Microglia	At	rest,	microglia	regulate	the	homeostasis	of	the	brain	but,	if	activated,	become	the	resident	macrophages	of	the	central	nervous	system	involved	in	the	immune	defence	mechanism.	 	They	account	 for	10-15%	of	 the	non-neuronal	brain	cells.	There	 is	 significant	 controversy	 regarding	 the	 precise	 nature	 of	 microglial	progenitors.	It	has	been	suggested	that	microglia	could	arise	from	intrinsic	brain	embryonic	progenitor	cells.		It	has	also	proposed	that	they	could	originate	from	meningeal	macrophages	 penetrating	 the	 brain	 during	 embryonic	development.		There	is	still	uncertainty	about	what	proportion	of	the	microglia	are	derived	from	
blood	 monocytes	 and	 it	 is	 possible	 that	 monocytes	 may	 be	 recruited	 to	 the	neonatal	 and	 adult	 brain	 when	 there	 is	 an	 injury	 and	 then	 differentiate	 into	microglial	cells.	While	there	is	controversy	regarding	the	origin	of	microglial	cells,	the	consensus	is	that	microglial	differentiation	occurred	primarily	in	the	central	nervous	system	[1].	While	it	has	been	shown	that	microglial	progenitors	invade	the	brain	in	the	early	stages,	it	is	now	established	that	microglia	arise	from	the	yolk	 sac	 [2].	 Microglia	 serve	 as	 a	 part	 of	 the	 innate	 immune	 system	which	 is	constantly	scanning	and	surveying	signals	for	any	danger	to	the	brain	cells.	As	a	primary	 response	 to	 injury,	microglia	become	activated	 in	order	 to	protect	 the	central	 nervous	 system	 from	 tissue	 damage	 and	 facilitate	 tissue	 repair	 and	clearance.	Microglia	also	contribute	to	the	control	of	neuronal	proliferation	and	differentiation	and	influence	synaptic	connections.		It	has	been	shown	that	there	is	an	interaction	between	the	microglia	and	synaptic	connections	in	the	healthy	brain.		Microglia	help	regulate	the	wiring	of	the	brain	circuits	allowing	adaptive	recovery	processes	to	occur	and	control	the	growth	of	dopaminergic	axons	and	neocortical	neurons	[3,	4].					While	the	origin	of	microglia	has	been	debated,	it	seems	clear	that	microglia	are	of	monocyte	 lineage	 and	 present	 in	 the	 brain	 from	 birth.	 They	 are	 the	 resident	macrophages	of	the	central	nervous	system	which	constantly	survey	the	brain	to	maintain	 normal	 homeostasis.	 During	 normal	 homeostasis,	 they	 maintain	 the	plasticity	of	the	neuronal	circuit	and	contribute	to	the	protection	and	remodelling	of	 the	 synapses.	 	 It	 has	 been	 suggested	 this	 protective	 effect	 of	 microglia	 is	mediated	 by	 the	 release	 of	 trophic	 factors	 such	 as	 brain-derived	 neurotrophic	factors	which	 are	 implicated	 in	memory	 formation.	 Resting	microglia	 exhibit	 a	highly	 ramified	 morphology,	 which	 can	 exceed	 50	 µm	 in	 length,	 suitable	 for	monitoring	the	environment.	 	 In	response	to	an	activating	signal,	 they	begin	to	withdraw	the	ramified	branches	(the	withdrawal	stage).	When	these	processes	are	withdrawn,	 new	 protrusions	may	 appear	 (the	 transitional	 stage)	 and	 then	move	on	to	a	motile	stage	where	the	newly	generated	protrusions	can	grow	and	shrink	at	a	rate	exceeding	4	µm	per	minute.		These	motile	cells	begin	to	contact	the	neighbouring	cells	and,	during	the	motile	stage,	microglia	can	move	through	the	tissue	at	the	rate	of	110	µm	per	hour	and	engulf	other	cells	[5].				It	has	also	been	established	 that,	while	microglia	engulf	dead	cells	 and	cellular	debris,	 they	can	also	transiently	ensheath	a	cell	sized	object	and	then	move	on	without	 ingesting	 the	object.	These	 transient	ensheathing	events	 indicate	 their	dynamic	nature	and	possible	role	in	tissue	surveillance.	 	It	is	proposed	that	this	transient	 ensheathing	 (frisking),	 where	 the	 frisked	 object	 may	 very	 well	 be	neurons	 or	 other	 cells	which	maintain	 the	 normal	milieu	 of	 the	 brain	 plays	 a	protective	role	as	does	the	microglial	responsibility	for	clearance	of	Aβ	and	other	toxic	proteins	from	the	brain.		Amyloid-beta	 (Ab)	 clearance	 is	 an	 important	 process	 of	microglial	 function.	 In	Alzheimer’s	 disease,	 microglia	 can	 bind	 to	 soluble	 amyloid-β	 oligomers	 and	amyloid-β	 fibrils	 via	 cell-surface	 receptors.	 The	 cell	 surface	 receptors	 include	CD36,	CD14,	a6	b1	integrin,	CD47	and	TLR	(TLR2	TLR4,	TLR6	and	TLR9).	It	has	been	shown	that	CD36,	TLR4	and	TLR6	trigger	a	pro-inflammatory	response	while	
binding	Ab.	Further	experiments	have	demonstrated	that	deletion	of	CD36,	TLR4,	and	TLR6	reduces	Ab	induced	cytokine	production	and	amyloid	accumulation.		Microglia	 engulf	 Ab	 fibrils	 by	 phagocytosis	 whilst	 soluble	 Ab	 is	 degraded	 by	various	extracellular	proteases	[6].	Microglia	contribute	to	CNS	homeostasis	and	neuroprotection	 during	 development	 by	 synaptic	 pruning	 and	 phagocytosis	 of	redundant	 neurons.	 They	 are	 involved	 in	 cortical	 laminar	 formation	 and	 axon	bundle	 fasciculation.	 It	 has	 been	 shown	 that	 peripherally	 delivered	 LPS	 can	activate	 TLR	 receptors	on	 the	 luminal	 surface	 of	 brain	 endothelial	 cells,	which	then	 secrete	 cytokines	 and	 activate	 microglia.	 It	 has	 been	 demonstrated	 that	activated	microglia	can	strip	axosomatic	inhibitory	synapses	from	neuronal	soma	which	induces	neuroprotection	by	upregulation	of	BCL1,	FGF2,	or	MCL1,	which	are	anti-apoptotic	molecules.	These	microglia	can	assume	an	M2-AP	phenotype	able	 to	 secrete	 ceruloplasmin,	CD163,	 SAA3,	YM-1,	 and	MSR1	during	 the	 initial	phase	of	neuronal	injury	[7].		
	It	is	generally	accepted	that	phenotypes	of	microglia	fall	into	two	main	classes:	(1)		A	pro-inflammatory	or	M1	phenotype	which	is	activated	the	classical	complememt	pathway	and	changes	in	brain	milieu.	(2)	An	anti-inflammatory	or	M2	phenotype	which	 is	 activated	by	 the	 alternative	 complement	pathway.	The	M1	phenotype	responds	 to	 lipopolysaccharide	 (LPS)	 in	 combination	 with	 interferon	 gamma	((IFN-γ), leading to a massive inflammatory response producing cytokines including 
interleukin-1β, IL-12, TNF-α, and inducible nitric oxide (iNOS).	The	M2	phenotype	has	three	sub-phenotypes,	M2a,	which	usually	responds	to	IL-4	and	IL-13,	while	M2b	 is	 stimulated	 by	 TLR	 or	 IL-1βactivation.	 M2c	 represents	 the	 deactivated	macrophages	and	contributes	to	the	suppression	of	pro-inflammatory	cytokines.	
[8, 9].	It	has	been	suggested	that	these	phenotypes	can	interconvert	depending	on	the	stimuli	and	so	models	based	purely	on	 inducing	an	M1	or	M2	phenotype	 is	over	 simplistic.	 	 Despite	 this,	 a	 simplified	 model	 where	 pro-inflammatory	phenotypes	 are	 regarded	 to	 be	 predominantly	 detrimental	 while	 anti-inflammatory	phenotypes	are	regarded	as	predominantly	involved	in	the	repair	process	of	the	neurons	has	proved	useful.	 	While	 there	 is	 evidence	 to	 suggest	microglial	activation	 can	be	deleterious,	 the	beneficial	effect	is	highlighted	in	circumstances	where	repair	is	happening,	as	in	after	stroke,	during	myelin	repair,	removal	of	toxic	aggregated	proteins	and	cell	debris	 from	 the	 CNS,	 as	 well	 as	 secretion	 of	 neurotrophic	 factors	 to	 prevent	neuronal	injury	[10-12].			While	it	is	agreed	that	the	M1/M2	microglial	classification	is	an	over	simplified	model,	these	two	phenotypes	have	been	studied	extensively	in	cell	culture	and	it	has	been	demonstrated	that	the	relative	populations	have	differential	influences	over	pathological	outcome	in	CNS	human	diseases.		
Astrocytes.		Astrocytes	are	glial	cells	characterised	by	star-shaped	cell	bodies	with	a	number	of	 processes.	 There	 are	 two	 types	 of	 astrocytes;	 (1)	 Protoplasmic	 astrocytes,	which	 are	 found	 in	 the	 grey	 matter	 and	 their	 processes	 end	 in	 sheet	 like	
appendages.	(2)	Fibrous	astrocytes,	which	are	found	in	the	white	matter	and	have	long	fine	processes.	While	the	function	of	astrocytes	is	still	debated,	it	is	generally	thought	that	they	provide	nutrition	for	neurones	and	insulate	nerves	and	synaptic	connections	from	each	other.	They	help	regulate	the	potassium	concentration	in	the	 space	 between	 the	 neurons[13].	 More	 importantly,	 they	 perform	 the	housekeeping	chores	that	promote	efficient	signalling	between	neurons	and	they	maintain	surrounding	neurons	by	releasing	growth	factors.		Astrocytes	enfold	all	the	blood	vessels	of	the	brain	and	ensheath	synapses.	As	their	physical	 association	with	 synapses	 is	 closer	 than	 1µm,	 astrocytes	 can	 regulate	local	extracellular	concentration	of	ions,	neurotransmitters	and	other	molecules.	The	 pathological	 response	 of	 astrocytes	 is	 reactive	 astrogliosis	 forming	 scars	whereas	 remodelling	 of	 astrocytes	 is	 generally	 aimed	 at	 neuroprotection	 and	recovery	of	injured	neuronal	tissue[14,	15].	Reactive	astrocytes	are	characterised	by	increased	expression	of	glial	fibrillary	acidic	protein	(GFAP).	However,	many	healthy	astrocytes	do	not	express	detectable	levels	of	GFAP	and	the	expression	of	GFAP	 can	 depend	 on	 the	 anatomical	 location	 of	 the	 astrocytes	 as	 well	 as	 the	species	 in	which	GFAP	expression	 is	being	examined.	Ageing	 is	 the	 leading	risk	factor	 for	 the	 common	 dementias,	 and	 astrocytes	 in	 the	 ageing	 brain	 show	features	 of	 senescence	 and	 expression	 of	 a	 senescence	 associated	 secretory	phenotype	(SASP).		Initially	 it	 was	 thought	 that	 astrocytes	 appeared	 activated	 in	 AD	 brain	 as	 a	secondary	or	non-specific	response	to	the	disease	process	[16].	However,	it	is	now	understood	 that	 astrocytes	 are	 central	 to	 the	 pathogenic	 mechanism	 in	neurodegeneration.	 This	 could	 be	 due	 to	 their	 production	 of	 cytokines	 and	chemokines	or	loss	of	physiological	functions	such	as	neuronal	support	and	spatial	buffering.	It	has	been	suggested	that	disruption	of	normal	glioneuronal	interaction	can	lead	to	synaptic	dysfunction	and	contribute	to	cognitive	impairment	[15,	17].	Wyss-Corey	et	al.	first	demonstrated	in	vitro	that	astrocytes	are	able	to	take	up	and	 degrade	 Aβ	 using	 cultured	mouse	 astrocytes.	 Histopathological	 studies	 of	Alzheimer	 brain	 have	 shown	 the	 presence	 of	 astrocytes	 which	 contain	 Aβ	suggesting	they	are	involved	in	the	clearance	of	this	peptide	[18-21].	Engulfment	of		Aβ	by	astrocytes,	however,	can	lead	to	their	death	and	give	rise	to	secondary	plaques	[21].			The	 mechanisms	 governing	 the	 receptor-mediated	 uptake	 of	 Aβ	 and	 its	consequences	are	not	fully	understood.	For	instance,	does	uptake	of	Aβ	induce	a	change	in	astrocyte	phenotype	so	altering	their	usual	neurosupportive	function.	Low	 density	 lipoprotein	 receptor-related	 protein	 1	 (LRP1)	 is	 involved	 in	 the	uptake	and	clearance	of	Aβ	and	 is	also	a	receptor	 for	 the	uptake	of	ApoE4	and	complexes	 of	 ApoE-Aβ	 highlighting	 the	 importance	 of	 this	 receptor	 in	 the	astrocytic	clearance	of	Aβ	[22-24].			Neuroinflammation	is	a	prominent	and	early	feature	of	Alzheimer's	disease	which	plays	 a	 key	 role	 in	 modulating	 the	 progression	 of	 disease	 via	 inflammatory	mediators	and	neurotoxic	compounds.	It	has	also	been	suggested	that	an	astrocyte	mediated	 inflammatory	 response	 can	 contribute	 to	 the	 neurodegenerative	process	 through	 expression	 of	 pro-inflammatory	 cytokines	 and	 chemokines,	
activation	 of	 complement	 cascade	 as	 well	 as	 reactive	 oxygen	 and	 nitrogen	species[25-27].	Studies	also	show	that	astrocytes	can	suppress	innate	immunity	through			αB-crystallin	suggesting	that	they	have	a	more	deleterious	influence	on	neuroinflammation.	 In	 animal	 models	 of	 AD	 it	 has	 also	 been	 shown	 that	 the	astrocyte	 contribution	 to	 neuroinflammation	 is	 significant	 and	 an	 important	therapeutic	target	[28,	29].			Apart	from	microglia	and	astrocytes,	other	cells	such	as	blood	derived	monocytes	may	also	play	a	significant	role	in	Alzheimer's	disease	(AD).	However,	the	precise	role	of	these	cells	in	human	studies	is	unclear	although	there	are	animal	studies	demonstrating	infiltration	of	these	peripheral	mononuclear	cells	associated	with	amyloid	deposition.	Ablation	of	CD11b-positive	 cells	 in	APP/PS1	models	of	AD	have	suggested	that	peripheral	monocytes	do	play	an	important	role	in	clearing	amyloid	plaques	[11,	30].				
P2X7	receptor.			The	 purinergic	 P2X7	 receptor	 (P2X7R)	 plays	 an	 important	 role	 in	 the	 central	nervous	system	binding	ATP.	The	P2XR	is	expressed	by	activated	microglia	and,	following	 brain	 injury,	 ATP	 can	 be	 released	 in	 large	 quantities	 leading	 to	stimulation	 of	 low	 affinity	 P2X7Rs	 resulting	 in	 glial	 necrosis/apoptosis	 or	proliferation,	demonstrating	two	opposing	effects	of	neuroinflammation	[31,	32].				P2X7Rs	or	ATP-gated	non-selective	 cation	 channels	are	made	up	of	595	amino	acid	 subunits.	 The	 common	 structural	 motifs	 of	 P2X7R	 are	 the	 two	transmembrane	domains	and	a	large	glycosylated	cysteine-rich	extracellular	loop	as	short	 intracellular	and	terminal	domain	and	 intracellular	C-terminal	domain	[33-35].	Activation	of	P2X7R	results	in	the	opening	of	the	channel	pore,	allowing	the	passage	of	small	cations	(Na+,	Ca+	and	K+).	Additionally,	P2X7	is	characterised	by	 opening	 of	 a	 non-selective	 pore	 in	 response	 to	 repeated	 or	 prolonged	activation,	allowing	permeation	of	larger	molecular	weight	organic	cations		up	to	600-800	Da.	Patency	of	the	large	pore	eventually	results	in	membrane	blebbing	and	cell	death	[36-38].					Cytokines	 are	 the	 major	 mediators	 of	 neuroinflammation,	 including	 pro-inflammatory	 and	 anti-inflammatory	 processes,	 chemo-attraction	 and	 Aβ	deposition	in	response	to	microglial	activation.	It	has	also	been	suggested	that,	as	Aβ	concentration	 increases	 in	ageing	 transgenic	mouse	models,	 it	 is	 associated	with	increased	levels	of	the	cytokines	TNF-a,		IL-6,	interleukin	1-α	and	GM-CSF,	suggesting	 pathological	 accumulation	 of	 Aβ	 could	 drive	 a	 neuroinflammatory	response	[39-41].				Chemokines	 regulate	 microglial	 migration	 to	 areas	 of	 neuroinflammation	 and	enhance	local	inflammation	in	Alzheimer's	disease.	There	is	upregulation	of	CCL2,	CCR3	and	CCR5	expression	by	microglia,	whereas	CCL4	is	expressed	by	reactive	astrocytes.	 	 It	 has	 been	 shown	 that	 Aβ	 deposition	 leads	 to	 generation	 of	interleukin-8,	CCL2,	and	CCL3.		It	has	also	been	suggested	that	CX3CR1/CX3CL1	is	involved	in	neuronal	survival,	plaque	load	and	cognition	[42-44].				
The	 complement	 system	 is	 a	 major	 constituent	 of	 the	 immune	 system	 in	 the	defence	 against	 pathogens.	 	 Activation	 of	 the	 proteolytic	 complement	 cascade	results	 in	opsonisation.	 	Major	sources	of	 complement	 system	proteins	 include	microglia	and,	to	a	lesser	extent,	astrocytes	[45,	46].	It	has	also	been	shown	that	Aβ	can	activate	the	complement	pathway.		The	protein	clusterin	is	involved	in	the	processing	 and	 clearance	 of	 immune	 complexes	 and	 is	 also	 a	 regulator	 of	 C3	convertase	activity.	Raised	clusterin	levels	are	associated	with	an	increased	risk	of	Alzheimer's	disease.		
PET	imaging	of	neuroinflammation.		Studies	 have	 shown	 microglial	 activation	 to	 be	 	 a	 component	 of	 many	 CNS	disorders	including	multiple	sclerosis,	focal	epilepsy,	stroke	and	brain	tumours.	It	is	clear	that	all	neurodegenerative	diseases	are	associated	with	significant	levels	of	neuroinflammation	 	but	 that	 this	 inflammatory	process	 is	different	 from	 the	autoimmune	diseases	of	brain.	While	in	relapsing	remitting	multiple	sclerosis,	it	has	been	shown	that	the	inflammatory	process	is	accompanied	by	T-cell	activation	with	 specificity	 for	 CNS	 antigen	 infiltrates,	 the	 inflammatory	 reaction	 in	Alzheimer's	disease	is	associated	with	activation	of	microglia	in	close	proximity	to	Aβ	 plaques	 [47,	 48].	 During	 the	 activation	 process,	 microglia	 express	 the	translocator	protein	(TSPO)	-	previously	known	as	the	peripheral	benzodiazepine	receptor	 (PBR)-	on	 the	outer	 surface	of	 their	mitochondria.	This	protein	binds	isoquinolines	such	as	PK11195,	and	diazepam,	and	is	present	in	peripheral	tissues	such	 as	 kidney,	 liver	 and	 lungs.	 It	 was	 later	 demonstrated	 that	 TSPO/PBR	 is	different	from	the	central	benzodiazepine	receptor	which	is	a	component	of	the	GABAA	 complex	 found	 in	 the	 central	 nervous	 system	 [49].	 TSPO	 forms	 a	multimeric	 complex	 with	 a	 32	 kDa	 voltage	 dependent	 anion	 channel	 called	mitochondrial	 porin	 and	 30	 kDa	 adenine	 nucleotide	 carrier	 in	 the	 outer	mitochondrial	 membrane[49,	 50].	 Recent	 studies	 have	 shown	 that	 TSPO	transports	cholesterol,	anions,	and	other	substrates	across	the	mitochondria	and	helps	maintain	the	membrane	potential	[51,	52].				The	 enzyme	 monoamine	 oxidase	 B	 (MAO-B)	 is	 expressed	 by	 astrocytes	 and		hydrolyses	trace	amines,	phenylethyl	amine	and	dopamine.		It	binds	deprenyl	and	D2-deprenyl.	MAO-B	expression	increases	with	age	and	is	thought	to	contribute	to	age-related	neurodegeneration.	 	Astrocytes	upregulate	expression	of	MAO-B	under	 physiological	 and	 pathological	 conditions	 and	 so	 levels	 of	 brain	MAO-B	reflect	astrocytosis.		Arachidonic	 acid	 is	 a	 polyunsaturated	 omega-6	 fatty	 acid	 present	 in	 the	phospholipid	bilayer	membranes	 in	 the	brain.	 	 It	serves	as	a	second	messenger	and	 is	 involved	 in	 the	 upregulation	 of	 several	 signalling	 enzymes.	 	 It	 is	 now	considered	 that	 arachidonic	 acid	 plays	 an	 important	 role	 in	 the	 inflammatory	process.		It	has	been	suggested	that	binding	of	cytokines	derived	from	microglia	to	calcium	channel	receptors	on	astrocytes	activates	phospholipase	enzyme	that	releases	 arachidonic	 acid	 from	 membrane	 lipoproteins.	 	 Owing	 to	 these	properties,	 arachidonic	 acid	 has	 been	 suggested	 to	 be	 a	 useful	 marker	 of	neuroinflammation.	 	 Additionally,	 cyclooxygenase	 catalyses	 the	 breakdown	 of	arachidonic	acid	into	prostaglandins.		There	are	two	isoforms	of	cyclooxygenase,	
Cox-1	and	Cox	-2,	where	Cox-1	is	predominantly	found	in	microglia	whereas	Cox-2	 is	 expressed	 post-synaptically	 in	 neurons	 in	 the	 cortex,	 amygdala	 and	hippocampus	[53].	Cox	is	also	involved	in	the	inflammatory	cascade	and	is	thus	considered	as	a	biomarker	for	neuroinflammation.		
Imaging	translocator	protein	(TSPO)		There	 are	 several	 TSPO	 radioligands	 which	 have	 used	 to	 detect	 microglial	activation	in	vivo	in	humans.		Please	see	table	1	for	the	details	of	these	studies	and	the	TSPO	radiotracers.	The	TSPO	radiotracer	that	has	been	most	widely	used	 is	[11C]-R-PK11195,	an	isoquinoline	 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline	carboxamide].		It	is	a	selective	antagonist	for	TSPO	and,	during	the	development	of	 this	 radiotracer,	 it	 was	 shown	 that	 the	 R-enantiomer	 has	 two-fold	 higher	affinity	 for	TSPO	compared	 to	 the	S-enantiomer.	 Initial	 studies	with	PK11195	were	conducted	more	than	two	decades	ago,	following	which	many	papers	have	been	published	demonstrating	neuroinflammation	can	be	detected	in	a	variety	of	neurodegenerative	diseases	and	in	neuroinflammatory	conditions	[54-57].				Cagnin	et	al	reported	the	first	Alzheimer's	disease	study	with	11C-PK11195	PET	and	 reported	up	 to	 	 40%	 increases	 in	 temporal	 lobe	 binding	 using	 a	 region	 of	interest	approach	[58].	Increased	microglial	activation	with	aging	was	also	seen.	Subsequent	 studies	 generally	 confirmed	 the	 increased	 11C-PK11195	 uptake	 in	Alzheimer's	brain,	though	some	studies	failed	to	detect	this	[59-61].			Studies	 have	 also	 evaluated	 the	 relationship	 between	 amyloid	 load	 and	neuroinflammation.	It	has	been	reported	that	neuroinflammation	correlates	with	amyloid	load	in	Alzheimer	and	mild	cognitive	impairment	(MCI)	cases	with	raised	amyloid	 deposition.	 While	 clusters	 of	 significant	 correlation	 between	 amyloid	deposition	and	neuroinflammation	have	been	demonstrated,	these	studies	have	also	 shown	 regional	 discrepancy	 between	 these	 two	 pathological	 processes,	suggesting	that	neuroinflammation	could	also	be	triggered	by	other	pathologies	such	as	tau	tangles	and	alpha	synuclein	aggregation.		It	has	also	been	pointed	out	that,	while	we	are	able	to	image	amyloid	deposition	using	imaging	ligands	for	beta	sheeted	protein,	we	are	still	unable	to	detect	oligomeric	β-amyloid	which	is	most	likely	 the	 toxic	 species	 contributing	 to	 the	 microglial	 activation	 [62,	 63].	 The	trajectories	 of	 amyloid	 aggregation	 and	 microglial	 activation	 are	 likely	 to	 be	different	 as	 the	 first	 precedes	 the	 second	 and	 rises	 to	 a	 stable	 level	 while	inflammation	 rises	 and	 then	may	 fall.	 Whether	 correlations	 are	 seen	 between	amyloid	and	PK11195	uptake	in	brain	regions	may	depend	on	the	time	point	of	the	disease.	While	positive	correlations	have	been	detected	between	PK11195	and	PIB	uptake,	one	group	could	not	demonstrate	any	such	correlation,	while	another	group	found	a	negative	correlation	between	amyloid	and	neuroinflammation	[60,	64].		Longitudinal	studies	on	preclinical	and	prodromal	Alzheimer	cases	are	really	needed	 to	 sort	 this	 inter-relationship	 out.	 As	 other	 pathologies	 could	 also	contribute	 to	 neuroinflammation,	 the	 advent	 of	 tau	 imaging	 agents	 is	 now	allowing	 groups	 to	 evaluate	 the	 inter-relationships	 between	 amyloid,	 tau	 and	neuroinflammation.			
While	there	have	been	discrepancies	between	the	results	across	centres,	it	is	now	generally	 accepted	 that	 there	 is	 increased	 cortical	 microglial	 activation	 in	Alzheimer's	 disease	 most	 closely	 tracking	 an	 amyloid	 pattern.	 	 Several	 recent	studies	have	also	shown	that	there	is	increased	microglial	activation	in	amyloid	positive	MCI	subjects	and	that	 this	microglial	activation	can	be	seen	before	the	conversion	 to	 dementia.	 Measurement	 of	microglial	 activation	 using	 PK11195	PET	shows	increased	regional	tracer	binding	in	the	entorhinal,	temporoparietal,	and	 cingulate	 cortex	 in	 Alzheimer's	 disease	 and	 mild	 cognitive	 impairment	subjects.	 It	 has	 also	 been	 shown	 that	 microglial	 activation	 is	 increased	 in	Parkinson's	 disease,	 Parkinson's	 disease	 with	 dementia,	 Lewy	 body	 dementia,	schizophrenia,	 traumatic	 brain	 injury,	 multiple	 sclerosis,	 stroke	 and	 several	neuroinflammatory	diseases.		Despite	the	demonstration	of	microglial	activation	in	 these	 conditions	 using	 PK11195	 PET	 tracer,	 there	 has	 been	 considerable	controversy	over	its	utility	because	of	its	relatively	low	signal-to-noise	ratio.	This	has	 led	 to	 the	 development	 of	 several	 novel	 second-generation	 TSPO	 PET	radiotracers	with	higher	affinity	and	lower	background	signals.		These	include	11C-PBR28,	 11C-DAA1106,	 11C-DPA713,	 18F-FEDAA1106,	 18F-PBR06,	 18F-FEPPA,	 18F-DPA-714,	and	18F-GE180.	[54,	65-70]				These	 second-generation	 TSPO	 PET	 tracers	 were	 developed	 to	 overcome	 the	shortcomings	of	11C-PK11195.	However,	one	of	the	main	limitations	of	the	second-generation	 TSPO	 tracers	 is	 that	 their	 binding	 is	 influenced	 by	 the	 TSPO	polymorphism	 expressed	 by	 subjects	 leading	 to	 differential	 binding	 across	 the	general	population	due	to	variations	in	TSPO	binding	affinity.	A	polymorphism	on	the	TSPO	gene	consisting	of	one	amino	acid	substitution	(Ala147Thr)	results	in		the	 population	 having	 a	 high	 affinity	 binding	 (HAB)	 phenotype,	mixed	 affinity	binding	 (MAB)	 phenotype	 or	 low	 affinity	 binding	 (LAB)	 phenotype	 for	 TSPO	ligands	other	 than	PK11195.	The	Ala/Ala	TSPO	genotype	 (wild-type)	 results	 in	HAB,	while	the	Ala/Thr	results	in	MAB,	and	Thr/Thr	results	in	LAB.	It	has	been	shown	that	roughly	50%	of	the	general	population	are	high	affinity	binders	while	around	40%	are	mixed	affinity	binders	and	10%	of	the	population	are	low	affinity	binders.	 Hence,	 for	 a	 homogeneous	 population,	 one	 should	 select	 high	 and/or	mixed	 affinity	 but	 not	 low	 affinity	 binders	 for	 study	with	 2nd	 generation	TSPO	tracers	[71].	While	concerns	have	been	raised	regarding	the	utility	of	the	studies	conducted	 in	 subgroups	 of	 the	 population,	 it	 has	 been	 demonstrated	 that,	 in	Alzheimer’s	 disease	 and	 MCI	 subjects,	 studies	 performed	 in	 apoE4	 or	 apoE3	genetic	subgroups	could	be	generalised	to	the	entire	AD/MCI	population,	at	least	in	observational	studies.	However,	one	could	speculate	that	this	could	hold	true	even	 in	 intervention	 studies,	 as	 long	 as	 the	 treatments	 were	 not	 influencing	cholesterol	metabolism.	Reference.			Studies	 using	 11C-PBR28	 have	 shown	 a	 very	 high	 specific	 signal	 for	microglial	activation	 with	 an	 increased	 80-fold	 affinity	 in	 animal	 models.	 Studies	 in	 AD	subjects	demonstrated	that	there	is	increased	microglial	activation	specifically	in	the	 inferior	 parietal	 lobule,	 precuneus,	 occipital	 cortex,	 hippocampus	 and	entorhinal	cortex	[68,	72].	However,	surprisingly	these	workers	were	unable	to	detect	inflammation	in	amyloid	positive	MCI	cases.			
Despite	 the	 significant	 interest	 in	 the	 second	 generation	 tracers,	 results	 using	[11C]PBR28	 have	 been	 inconsistent.	 While	 some	 groups	 have	 been	 able	 to	demonstrate	a	significant	difference	between	the	Alzheimer’s	disease	and	healthy	control	subjects,	 other	groups	were	unable	 to	show	consistent	differences.	The	average	percentage	increase	in	AD	subjects	compared	to	the	control	subjects	was	similar	to	that	seen	with	[11C](R)PK11195	PET	(around	30%).	While	no	head-to-head	study	has	compared	[11C]PBR28	and	[11C](R)PK11195	PET	in	AD,	there	is	no	convincing	evidence	to	suggest	that	one	tracer	is	more	sensitive	than	the	other.	As	 there	 is	 no	 typical	 reference	 devoid	 of	microglial	 activation	 in	 the	 brain	 in	neurodegenerative	diseases,	TSPO	ligands	are	also	affected	by	the	quantification	issues.	While	supervised	cluster	analysis	has	been	used	to	define	a	reference	tissue	cluster	 representing	normal	grey	matter	uptake	kinetics	 for	 [11C](R)PK11195,	such	 an	 approach	 has	 not	 been	 feasible	 for	 [11C]PBR28.	 Hence,	 a	 cerebellar	reference	has	been	used	to	reflect	non-specific	uptake	approach	for	[11C]PBR28	which	 is	 likely	 to	 overestimate	 this	 component.	 There	 is	 also	 considerable	variability	 in	 the	 plasma	 protein	 binding	 of	 TSPO	 ligands	 across	 subjects	 and	disease	 states	 [73-75].	 This	 makes	 using	 an	 arterial	 plasma	 input	 reference	function	difficult	due	to	the	variability	in	time	activity	curves.		Initial	studies	with	11C-DPA-713	demonstrated	that	it	provided	better	sensitivity	than	 11C-PK11195	 and	 showed	 more	 TSPO	 density	 in	 widespread	 regions	 of	ageing	subjects	and	also	AD	subjects	[76,	77].		While	[11C]DPA-713	was	being	evaluated,	a	newer,	higher	affinity,	higher	specific	to	non-specific	binding	tracer	with	a	longer	half-life,	[18F]DPA-714	was	developed	and	evaluated	[66,	78].	[18F]DPA-714	has	demonstrated	significant	increases	in	the	frontal,	temporal	and	parietal	cortex	of	Alzheimer	cases,	again	suggesting	that	microglial	 activation	 could	 be	 detected	 with	 both	 first	 and	 second	 generation	TSPO	 tracers.	 Interestingly,	 highest	 tracer	 binding	 was	 seen	 in	 prodromal	 AD	suggesting	that	inflammation	may	reduce	as	MCI	progresses	to	AD.			Other	second-generation	tracers	include	[18F]FEPPA,	where	PET	has	shown	that	there	 is	 significant	 uptake	 in	 the	 grey	 matter	 of	 the	 hippocampus,	 prefrontal	cortex,	temporal,	parietal,	occipital	cortex,	posterior	limb	of	internal	capsule,	and	cingulum	 of	 Alzheimer	 cases	 [79,	 80].	 [18F]FEMPA	 PET	 detected	 significant	uptake	 in	 the	medial	 and	 lateral	 temporal	 cortex,	 posterior	 cingulate,	 caudate,	putamen	 and	 thalamus	 in	 Alzheimer's	 disease.	 [11C]DAA-1106,	 [18F]FEDAA-1106	 and	 [11C]vinpocetine	 PET	 have	 also	 demonstrated	 significant	microglial	activation	in	Alzheimer's	disease	and	other	neurodegenerative	diseases.	Details	of	today's	choices	and	the	major	findings	are	listed	in	Table	1	[60,	65,	81].			In	 the	 early	 stages	 of	 Alzheimer's	 disease	 (amyloid-positive	 MCI	 subjects),	[11C]DAA-1106	 and	 [18F]DPA-714	 PET	 have	 demonstrated	 high	 increases	 in	binding	 in	 the	 frontal,	 temporal	 and	 parietal	 cortex.	 This	 was	 consistent	 with	previous	observations	using	[11C](R)PK11195	PET	[82].	While	initial	studies	with	11C-PBR28	failed	to	demonstrate	increased	microglial	activation	in	MCI	subjects,	recent	studies	have	shown	that	increased	microglial	activation	in	MCI	subjects	can	be	seen	on	a	single	subject	analysis.			
Microglial	activation	has	been	reported	in	AD	variants	such	as	posterior	cortical	atrophy,	 where	 PBR28	 has	 demonstrated	 significantly	 increased	 binding	 in	occipital,	posterior	parietal	 and	 temporal	 regions.	While	 there	have	been	 some	reports	concerning	correlation	with	age,	 later	 reports	using	[18F]DPA-714	 in	a	larger	cohort	have	not	shown	an	age	effect.	There	has	been	significant	negative	correlation	between	TSPO	binding	and	cognitive	performance	using	11C-PBR28,	[11C](R)PK11195	and	[18F]FEPPA.	Interestingly,	a	recent	study	in	a	large	number	of	AD	and	MCI	subjects	demonstrated	that	MMSE	was	positively	correlated	with	microglial	activation	[70].		Studies	have	already	demonstrated	that,	in	AD	subjects,	there	is	a	negative	correlation	between	microglial	activation	and	atrophy	while,	using	[18F]DPA-714,	microglial	activation	was	positively	correlated	with	the	grey	matter	 volume	 in	 MCI	 and	 AD	 patients.	 Studies	 have	 already	 demonstrated	correlations	 between	 amyloid	 load	 using	 [11C]PIB	 and	 [11C](R)PK11195,	[11C]PIB	 and	 [11C]PBR28	 and	 [18F]DPA714	 in	 different	 cortices,	 precuneus,	hippocampus	and	parahippocampal	gyrus.			
Longitudinal	evaluation	of	microglial	activation			There	 are	 only	 a	 handful	 of	 studies	 which	 have	 evaluated	 the	 longitudinal	relationship	 of	 microglial	 activation	 and	 disease	 progression.	 Fan	 et	 al.	demonstrated	 that	 there	 is	 increased	 microglial	 activation	 as	 the	 disease	progresses	in	established	Alzheimer's	disease,	while	in	mild	cognitive	impairment	subjects	 there	 was	 a	 longitudinal	 reduction.	 Please	 see	 figure	 1.	 The	 authors	argued	that	the	microglial	activation	detected	by	TSPO	tracers	in	the	early	and	late	stages	of	the	disease	could	be	phenotypically	different,	and	in	the	early	stage	of	the	disease	it	may	be	detecting	the	anti-inflammatory	phenotype	while	during	the	later	stages	of	the	disease	it	may	be	detecting	the	pro-inflammatory	phenotype.		It	has	 also	 been	 suggested	 that,	while	 the	 anti-inflammatory	 phenotype	 becomes	ineffective	 in	 clearing	 amyloid	 and	 toxic	 debris,	 there	 is	 progressive	 amyloid	deposition	and	neuronal	damage.		In	contrast,	as	the	disease	progresses	there	is	persistent	activation	of	the	pro-inflammatory	phenotype	which	is	also	detected	by	the	microglial	tracer	as	a	persistent	elevation	of	microglial	activation.		This	later	phase	of	microglial	activation	is	also	detected	by	the	TSPO	tracer,	and	continues	to	 rise	as	 the	disease	progresses	and	correlates	with	 the	 cognitive	 impairment	[83].			Kreisl	et	al.	demonstrated	that	 in	AD	subjects	 there	 is	 increased	binding	of	 11C-PBR28	 in	 the	 inferior	parietal	 lobule,	precuneus	occipital	 cortex,	hippocampus,	entorhinal	cortex,	middle	and	inferior	temporal	cortex.		Longitudinally	there	was	an	annual	increase	of	3.9	to	6.3%	in	patients	with	AD.		It	is	also	proposed	that	the	annual	rate	of	increased	TSPO	binding	in	the	tempoparietal	region	was	about	five	fold	higher	in	patients	with	clinical	progression	compared	to	those	who	did	not	progress	[84].			Hamelin	et	 al.	 evaluated	64	patients	with	Alzheimer's	disease	and	32	controls.		They	demonstrated	that	higher	microglial	activation	was	present	in	slow	decliners	compared	with	fast	decliners.		They	also	demonstrated	that	microglial	activation	is	present	in	prodromal	and	possibly	at	the	preclinical	stage	of	Alzheimer’s	disease	
and	was	found	to	play	a	protective	role	in	in	the	clinical	progression	of	the	disease.		This	study	 further	substantiates	 the	concept	 that	microglial	activation	could	be	protective	in	early	stages	of	the	disease	[70].			
Imaging	astrocyte	activation		L-deprenyl	 is	 an	 irreversible	 monoamine	 oxidase-B	 (MAO-B)	 inhibitor,	 which	exists	 on	 the	 outer	 mitochondrial	 membrane	 of	 astrocytes	 [85,	 86].	 The	radiotracer	 [11C]deuterium-L-deprenyl	 ([11C]DED)	 has	 high	 affinity	 and	specificity	 for	 MAO-B	 increases	 in	most	 brain	 regions	 in	 healthy	 older	 adults.		Activity	 of	 MAO-B	 increases	 in	 AD	 patients’	 brains	 where	 the	 enzyme	 is	 over	expressed	by	reactive	astrocytes.	 	Autoradiographic	studies	have	demonstrated	that	[11C]DED	can	be	used	as	an	in	vivo	PET	ligand	for	assessing	MAO-B	in	AD	brains.		In	a	study	of	eight	MCI	subjects,	seven	AD	subjects	and	14	healthy	controls	it	has	been	shown	that	there	is	increased	astrocyte	activation	in	the	left	temporal,	left	insular	cortex,	bilateral	anterior	cingulate,	right	parahippocampal	cortex,	right	hippocampus,	 right	 caudate	 and	 left	 putamen	 [87].	 It	 was	 also	 shown	 that	increased	[11C]DED	binding	to	MAO-B	was	more	evident	in	the	amyloid-positive	MCI	subjects	compared	to	the	amyloid-negative	subjects	and	Alzheimer’s	disease	subjects.		Novel	astrocyte	markers	are	being	tested	which	includes	markers	of	imidazoline	binding.	 Preliminary	 data	 using	 the	 tracer	 [11C]BU99008	 have	 demonstrated	significant	uptake	in	different	cortical	regions	in	healthy	control	subjects.	While	the	 results	of	 further	 studies	 are	 awaited,	 the	 results	 from	 the	 healthy	 control	subjects	are	promising.		While	it	is	recognised	that	neuroinflammation	is	a	prominent	and	early	feature	of	Alzheimer's	disease	which	plays	a	key	role	in	modulating	disease	progression,	the	role	 of	 astrocyte	 activation	 is	 still	 being	 debated.	 Several	 studies	 indicate	 that	astrocyte-mediated	 inflammatory	 processes	 also	 contribute	 to	neurodegeneration	 in	 AD	 through	 increased	 astrocytic	 expression	 of	 pro-inflammatory	cytokines	and	chemokines,	activation	of	the	complement	cascade	as	well	as	reactive	oxygen	and	nitrogen	species.	To	understand	the	role	of	astrocytes,	further	studies	are	necessary	using	in	vivo	imaging	agents	which	would	allow	us	to	track	the	progression	of	astrocyte	activation	longitudinally.		Novel	targets	of	neuroinflammation		Apart	from	targeting	TSPO,	further	work	is	necessary	to	develop	new	targets	to	detect	 the	migratory	 capacity	 of	microglia	or	 their	 ability	 to	 phagocytose	 toxic	products.		While	such	targets	could	be	of	very	significant	interest,	new	approaches	such	as	cell	type	specific	transcriptional	profiling	and	identification	of	numerous	cell	specific	changes	may	provide	a	challenge,	and	is	being	still	pursued	as	a	novel	strategy	to	identify	microglial	activation.			The	cannabinoid	type	2	receptor	(CB2R)	is	part	of	the	endogenous	cannabinoid	system	which	 is	 an	alternative	membrane	marker	of	microglial	 activation.	PET	tracers	 showing	 high	 affinity	 for	 CB2R	 have	 been	 developed,	 one	 of	 which	 is	
[11C]NE40.		However,	this	tracer	showed	lower	uptake	in	AD	patients	compared	to	the	control	subjects.			It	was	suggested	this	could	be	due	to	low	level	of	CB2R	expression	 and	 insufficient	 selectivity	 for	 CB2R.	 Several	 other	 high	 affinity	agonists	are	also	being	evaluated	as	CB2R	tracers,	such	as	[11C]MA2,	[18F]MA3,	[18F]RS126	[88,	89].				It	has	been	shown	that	[11C]KTP-Me	is	a	pro-radiotracer	for	ketoprofen	(KTP)	and	animal	studies	have	suggested	that	[11C]KTP	is	retained	in	inflammatory	lesions	due	to	the	expression	of	Cox-1.	While	a	first	human	study	in	healthy	volunteers	showed	that	[11C]KTP-Me	could	be	a	potential	PET	tracer	with	good	penetration	in	human	brain,	subsequent	studies	did	not	find	a	difference	between	controls	and	AD	subjects	 [90].	Nicotinic	 acetylcholine	 receptors	 (nAChR)	are	upregulated	 in	neuroinflammation.	The	ligand	targeting	a4b2	nAChR	has	been	demonstrated	to	have	 similar	 patterns	 of	 uptake	 as	 11C-PK11195.	 However,	 despite	 the	 initial	enthusiasm,	 several	 nicotinic	 acetylcholine	 receptor	 tracers	 have	 not	 been	successful.	New	compounds	such	as	[18F]ASEM	and	[18F]DBT-10	are	now	being	evaluated	[91].			Recent	 studies	 have	 shown	 that	 the	 P2X7	 receptor	 is	 widely	 present	 in	neuroinflammation.	 Studies	 have	 shown	 that	 deletion	 and	 pharmacological	blockade	 of	 P2X7Rs	 alter	 responsiveness	 in	 animal	 models	 of	 neurological	disorders.	 P2X7	 receptors	 are	 expressed	 in	 the	 cell-surface	 membrane	 of	haematopoietic	 cells	 such	 as	 macrophages	 and	 microglia.	 Novel	 PET	 tracers	targeting	 P2X7	 receptors	 include	 [11C]GSK1482160,	 [11C]A740003,	 [11C]JNJ-54173717.		Other	 targets	of	 interest	 include	phospholipase	A2	 (PLA2)	 activity.	 It	has	been	shown	that	inflammatory	cytokines	released	from	microglia	can	bind	to	astrocyte	receptors	which	are	coupled	to	PLA2.	When	this	enzyme	is	activated	it	hydrolyses	arachidonic	acid	(AA)	from	the	membrane.	Hence,	by	measuring	the	brain	uptake	of	[11C]arachidonic	acid,	one	could	determine	the	metabolic	loss	of	arachidonic	acid	in	the	brain.	It	was	proposed	that	increased	incorporation	of	[11C]AA	could	represent	upregulated	AA	metabolism	due	to	neuroinflammation.			Another	target	is	adenosine	A2A	receptors	(A2AR).	The	binding	of	adenosine	to	A2AR	tends	to	attenuate	inflammation	by	endogenously	limiting	the	inflammatory	response,	 and	 leads	 to	 up-regulation	 of	 these	 receptors	 at	 the	 sites	 of	inflammation.	While	these	mechanisms	have	been	proposed,	to	date	no	definite	tracer	which	could	replace	the	TSPO	tracer	has	been	developed.			
Conclusion:	
	It	 is	 now	 clear	 that	 neuroinflammation	 plays	 a	 significant	 role	 in	 Alzheimer's	disease	 and	 neurodegenerative	 diseases.	 	 Microglia	 and	 astrocytes	 play	 a	significant	 role	 in	 neuroinflammation,	 however,	 activation	 of	 microglia	 and	astrocytes	can	vary	depending	on	the	stage	of	the	disease	and	the	trajectories	are	still	 uncertain.	 While	 we	 are	 now	 able	 to	 image	 activation	 of	 microglia	 and	
astrocytes,	further	research	is	necessary	to	evaluate	whether	initially	they	have	a	protective	and	later	a	cidal	influence	on	neurodegeneration	as	some	series	have	suggested.	 There	 have	 been	 significant	 advances	 in	 imaging	 microglia,	 with	further	 recent	 advances	 in	 imaging	 astrocytes.	 More	 evidence	 is	 emerging	regarding	the	differential	role	of	microglial	and	astrocyte	activation	in	different	stages	of	neurodegenerative	disease,	which	will	form	the	basis	of	future	research	in	neuroinflammation	in	the	coming	decades.	As	there	are	many	other	processes	involved	in	neuroinflammation,	future	research	will	need	to	develop	biomarkers	to	evaluate	new	markers	such	as	chemokine	receptor	function	to	differentiate	the	pro-inflammatory	 and	 anti-inflammatory	 molecules	 involved	 in	neuroinflammation.	Current	evidence	suggests	that	not	all	the	neuroinflammatory	processes	 happening	 in	 the	 brain	 are	 detrimental,	 and	 further	 research	 is	necessary	to	separate	and	understand	them.		Key	words:		Microglia,	neuroinflammation,	astrocytes,	neurodegeneration,	Alzheimer’s	
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Figure1
		
Hypothetical	model	of	dual	peak	of	microglial	activation	in	the	Alzheimer’s	
trajectory.	 The	 upper	 panel	 demonstrates	 the	 hypothetical	 model	 of	morphological	 changes	 in	 microglia	 in	 Alzheimer’s	 disease	 trajectory,	 where	ramified	 microglia	 transform	 to	 anti-inflammatory	 (protective)	 microglial	phenotype	and	pro-inflammatory	(toxic)	microglial	phenotypes.	The	lower	panel	shows	the	microglial	activation	in	relation	to	other	biomarkers	detectable	using	positron	 emission	 tomography	 where	 two	 peaks	 of	 microglial	 activation	 are	present	in	Alzheimer’s	trajectory	(modified	from	Jack	et	al)	(Reprinted	from	Brain;	https://doi.org/10.1093/brain/aww349	
